Volcano Announces Launch of Valet® Microcatheter in the United States and Europe

  Volcano Announces Launch of Valet® Microcatheter in the United States and
                                    Europe

New Product Line Provides Unsurpassed Precision, Control and Support in
Complex Cases

PR Newswire

SAN DIEGO, March 14, 2013

SAN DIEGO, March 14, 2013 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC) a
leading developer and manufacturer of precision guided therapy tools designed
to enhance the diagnosis and treatment of coronary and peripheral vascular
disease, today announces the launch of the Valet^® microcatheter in the United
States and Europe.

Valet is a high performance microcatheter that is used for guidewire support,
wire exchange and contrast injections during complex coronary and peripheral
interventional procedures and is particularly useful for highly stenosed
lesions.

According to company officials, Valet is the first product to incorporate
Volcano's proprietary VeriTorque™ technology. VeriTorque™ technology provides
outstanding torque performance that, when combined with Valet's shapeable
distal tip, helps physicians precisely control and position their guidewire in
distal and tortuous anatomy. Valet also provides a new level of guidewire
crossing support on account of its seamless, powder coated shaft and
reinforced layers of microwire wind on the proximal segment of the catheter.

"The Valet microcatheter launch highlights Volcano's commitment to providing
precision guided therapies, specifically in the area of highly stenosed
lesions," said Scott Huennekens, President and CEO of Volcano Corporation.
"Highly stenosed lesions and complex lesions represent some of the most
challenging conditions an interventionalist may face. We believe a
microcatheter with ultra-high performance attributes like Valet will be
welcomed."

"Volcano has brought real innovation to the microcatheter--one of our front
line tools in treating chronic coronary artery occlusions," said Dr. Barry
Rutherford, Director of the Interventional Cardiology Research Program at St.
Luke's Mid America Heart Institute and the physician performing the product's
first U.S. in-man case. "I found the catheter to have excellent torque
response and superb handling and tracking." 

"Valet offers compelling performance benefits in challenging peripheral
endovascular cases. The combination of support, deliverability and guidewire
control is unique," commented Dr. Christos Katsigiannis, Cardiothoracic
Surgeon at Clear Lake Regional Medical Center and the surgeon performing the
first peripheral in-man cases with Valet. "I particularly appreciated Valet's
performance in navigating the complex anatomy below-the-knee."

The Valet microcatheter is available in sizes compatible with 0.014" and
0.035" guidewires and in lengths of 100cm, 135cm and 150cm. Additional
product information is available at www.volcanocorp.com.

About Volcano Corporation
Volcano Corporation is revolutionizing the medical device industry with a
broad suite of technologies that make imaging and therapy simpler, more
informative and less invasive. Its products empower physicians around the
world with a new generation of analytical tools that deliver more meaningful
information - using sound and light as the guiding elements. Founded in
cardiovascular care and expanding into other specialties, Volcano is changing
the assumption about what is possible in improving patient outcomes by
combining imaging and therapy together.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
the U.S. Private Securities Litigation Reform Act of 1995. Any statements in
this release that are not historical facts may be considered "forward-looking
statements" including statements regarding the potential benefits of the Valet
microcatheter, and other products, procedures and technologies described
above, the pace and extent of market adoption of the company's Valet
microcatheter product and other technologies, and the impact of clinical and
other technical data. Forward-looking statements are based on management's
current expectations and are subject to risks and uncertainties which may
cause Volcano's results to differ materially and adversely from the statements
contained herein. Some of the potential risks and uncertainties that could
cause actual results to differ include the pace and extent of market adoption
of the company's products and technologies; unexpected clinical trial results,
including unexpected new clinical data and unexpected additional analysis of
existing clinical data; unexpected regulatory actions or delays or government
regulation generally; the company's ability to obtain or maintain patent or
other proprietary intellectual property protection; competition in general;
government, industry and general public pricing pressures; unexpected
manufacturing issues; growth strategies; timing and achievement of product
development milestones; outcome of ongoing litigation; the impact and benefits
of market development; product introductions; unexpected new data, safety and
technical issues; market conditions; and other risks inherent to medical
device development and commercialization. These and additional risks and
uncertainties are more fully described in Volcano's filings made with the
Securities and Exchange Commission, including our recent annual report on
Form 10-K. Undue reliance should not be placed on forward-looking statements
which speak only as of the date they are made. Volcano undertakes no
obligation to update any forward-looking statements to reflect new
information, events or circumstances after the date they are made, or to
reflect the occurrence of unanticipated events.

SOURCE Volcano Corporation

Website: http://www.volcanocorp.com
Contact: Edrienne Brandon, +1-858-720-4136, ebrandon@volcanocorp.com ;
Investor Contact: Neal Rosen, +1-650-458-3014, nrosen@volcanocorp.com
 
Press spacebar to pause and continue. Press esc to stop.